Italy Fines Apple €98.6 Million Over App Store Dominance 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
NEW YORK, Aug. 30, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of purchasers of Dr. Reddy's Laboratories Limited American Depositary Receipts (“ADRs”) ("Dr. Reddy's" or the "Company") (NYSE:RDY) between June 17, 2015 and August 10, 2017, inclusive (“the Class Period”).
Investors who have incurred losses in Dr. Reddy's Laboratories Limited are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.
If you have purchased the ADRs of Dr. Reddy's Laboratories Limited and would like to assist with the litigation process as a lead plaintiff, you may, no later than October 24, 2017, request that the Court appoint you lead plaintiff of the proposed class.
Dr. Reddy's is a pharmaceutical company based in Hyderabad, India.
The filed complaint alleges that Dr. Reddy's lacked an effective corporate quality system, and as a result, defendants' public statements were materially false and misleading.
On November 6, 2015, Dr. Reddy's revealed that it had received a warning letter from the U.S. Food and Drug Administration (FDA) regarding inadequate quality control standards at three of its manufacturing plants in India. Following this news, the price of Dr. Reddy's ADRs fell 18%, to close at $53.50 on November 6, 2015.
On August 10, 2017, Dr. Reddy's revealed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices (GMP) compliance certificate of a formulations manufacturing unit of Dr. Reddy's German subsidiary, betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. On this news, the ADR price dropped $1.92 per share, or approximately 6%, on August 10, 2017.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774
